How tirzepatide dosing works — and why the schedule matters

Why does tirzepatide start so low, isn't 2.5 mg too small to do anything?

This is probably the most common misconception our prescribers hear. The 2.5 mg starting dose was not designed to drive weight loss; its job is to give your gut time to adapt to a medicine that works on two hormone receptors at once. Tirzepatide activates both GIP and GLP-1 pathways, which slows gastric emptying and reduces appetite, effects that can cause nausea, vomiting and digestive discomfort if introduced too quickly. Starting low keeps those effects manageable while your system acclimatises. Most people find the GI symptoms are most noticeable in the first week or two after a new dose, then settle. By the time you reach higher strengths, your tolerance is considerably better than it would have been had you started there. The tirzepatide overview covers the mechanism in more detail if you want the full picture on how both pathways contribute.

Clinical trial evidence (from SURMOUNT-1, published in the New England Journal of Medicine) showed average weight reductions of around 20–21% at the 15 mg dose over 72 weeks. That figure reflects participants who reached and maintained the maintenance dose, not those who stayed at 2.5 mg indefinitely.

How does the dosing of tirzepatide progress over time?

After the first four weeks at 2.5 mg, the schedule moves to 5 mg, then 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg, each step separated by roughly four weeks. That means reaching the maximum dose takes around five months from the first injection, assuming no pauses. Prescribers can slow the progression if side effects at a particular strength are difficult to manage, or hold at a dose that is working well without needing to push higher. The target is the highest dose you tolerate comfortably, which varies between individuals. Some people respond strongly at 10 mg; others benefit from continuing to 15 mg. No part of dosing tirzepatide should be self-directed, each progression requires a clinical re-review, and at nume that review happens before every repeat order.

If you are curious about the schedule expressed in the injection-volume terms used by some compounding contexts, the tirzepatide dosing in units page explains how the licensed KwikPen differs from those presentations. For weight-loss-specific framing of the schedule, dosing tirzepatide for weight loss focuses on what the evidence says about results at each level.

What does NICE say about when to stop or continue?

NICE's recommendation on tirzepatide (TA1026, published December 2024 and updated September 2025) includes a practical review point: if a patient has not lost at least 5% of their body weight after six months at the highest dose they can tolerate, continuing is subject to review. That threshold exists because the medicine's clinical benefit is tied to meaningful weight reduction, and keeping someone on an ineffective regimen carries unnecessary cost and side-effect exposure. It is worth noting that this review applies to the highest tolerated dose, not to 2.5 mg or any early-titration strength. Reaching that review point is not a failure; it is the system working as designed, prompting a clinical conversation about next steps.

The NICE eligibility criteria cover adults with a BMI of 35 or above plus at least one weight-related condition for NHS access, though private routes (including Mounjaro through a private pharmacy) follow the licensed criteria in the SmPC, which permits treatment from BMI 30 (or 27 with a qualifying condition). Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber always considers the whole clinical picture, not BMI alone.

What should you do if a dose increase causes side effects?

Some degree of nausea, loose stools or reduced appetite after a step up is expected and usually short-lived. Eating smaller portions, staying well hydrated and avoiding fatty or spicy foods in the first week after an increase helps most people through. The Mounjaro dosing page covers practical management tips in detail. What warrants urgent medical attention is different: severe, persistent stomach pain that spreads to the back (possibly accompanied by vomiting) should be assessed the same day, as this can be a sign of pancreatitis, an infrequent but serious risk highlighted by the MHRA in its January 2026 Drug Safety Update for GLP-1 medicines. Report any suspected adverse effects, including unexpected reactions at dose increases, via the MHRA Yellow Card scheme.

Never increase your dose ahead of schedule without speaking to your prescriber, and never reduce or stop without clinical guidance either, abrupt changes can affect how well the medicine works and increase the chance of rebound. If a particular strength consistently causes problems, the right move is a clinical conversation, not a self-adjustment. That is exactly the kind of question our aftercare team is available for, seven days a week.

For a broader look at treatment options and whether tirzepatide might suit your circumstances, the free consultation page is the place to start, a GPhC-registered prescriber reviews every assessment the same day it is submitted.